EVQLV’s Evolutionary Algorithm Explained

Jun 23, 2020 | Blog | 2 comments

Bhoomika Kumar

Our technology works by taking an antibody sequence of interest and performing evolutionary modeled mutagenesis, mimicking the natural selection inherent to antibody VDJ recombination and affinity maturation. Using large amounts of public and proprietary sequence data (e.g., PDB, IMGT, human antibody repertoires), our algorithm infers the patterns of evolutionarily likely fragment variable mutations. Biosequence analysis using hidden Markov Models allows for the consideration of sequences that are homologous to the reference antibody chain of interest, and the frequency of different amino acids at various positions, relative to the presence of other amino acids (epistatic modeling) is used to generate a heatmap of evolutionarily possible mutations at each position of the chain. 

In order to achieve higher-order mutational states, the algorithm traverses from first-order mutation, to second, to third and so on by exploiting the likely evolutionary possibilities. The machine searches for the best tactic, in a given mutational state, with the goal of maximizing positive likelihood in evolution. Our algorithms raise overall positive evolutionary likelihood at levels as high as 13 mutations. The algorithm is able to achieve higher order levels of mutational complexity, which could augment the work performed in the lab, all without significant time and cost.

The next step in our pipeline is the screening of the 1-2 million most evolutionarily-likely antibody variants along a host several factors such as temperature, stability, solubility, aggregation propensity, in addition to amino acid characterizations.  The performances of the generated sequences are compared to Phase III and FDA approved antibodies that are run through the same in silico assays. The algorithm then selects AI-generated antibodies that fit within the distribution of Phase 3 and FDA approved antibodies. 

Applying these in silico characterization methods enable early identification of risks such as  immunogenicity, instability, aggregation, high viscosity, or poor expression which can all preclude an antibody from becoming a therapeutic. While success is not guaranteed, this pipeline prevents developability issues early on in order to reduce downstream development risks. 

The most promising sequences from these in-silico assays are clustered by mutational and characteristic features. Both of these clustering approaches are employed so that we may produce highly diverse panels for our collaborators while working within their budget constraints. As an important note, this clustering process is not two or 3-dimensional, which is the extent of human visual perception. This is an over 80 dimensional clustering model that accounts for as much diversity as possible. 

We perform computational structure modeling to assess candidates from each cluster for binding affinity using Rosetta. Through a highly distributed file system, the relative docking scores for all the antibodies are rapidly computed and scored. 

From input of amino acid sequence, the algorithm computationally generates evolutionarily possible sequences with high affinity and lower likelihood of failure in less than a week. By failing as much as possible in the computer, wet lab researchers save immeasurable cost, time, and resources, allowing for significant acceleration of pre-clinical drug development.

Learn more about EVQLV here.

2 Comments

  1. Alex F

    Wow. Fascinating. Great work, Bhoomika.

    Reply
  2. Fred Berg

    “The next step in our pipeline is the screening of the 1-2 million most evolutionarily-likely antibody variants along a host several factors such as temperature, stability, solubility, aggregation propensity, in addition to amino acid characterizations.”

    I would be interested in learning more about this

    Reply

Submit a Comment

Your email address will not be published. Required fields are marked *

Large Pharma’s Embrace of Artificial Intelligence

The benefits of computational drug development are well known and accepted by many in the pharmaceutical space. However, since the onset of the global pandemic, consensus went from it being an interesting concept that was almost certainly the future, to something we need implemented as soon as possible. This is one of the few silver linings of the coronavirus outbreak.

The depth, vision and progress of EVQLV

Our CEO, Andrew Satz, recently spoke at Columbia University School of General Studies’ “Alumni in Action.” The subject of his talk was artificial intelligence. One of the questions posed to Andrew was what we were doing outside of coronavirus, along with the long term plans of our company

EVQLV Applies Proprietary AI Technology in Collaboration with Twist Bioscience to Discover and Validate Novel Antibody Therapies

EVQLV, Inc., an artificial intelligence-enabled technology company accelerating biologics discovery, announced today a collaboration with Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, to discover novel antibody-based therapies.

EVQLV’s Evolutionary Algorithm Explained

Brett Averso (CTO, EVQLV) and Bhoomika Kumar (SciTech intern, EVQLV) teamed up to provide a high-level overview of how EVQLV’s evolutionary algorithm works.

Andrew Satz on the Talent Finders Podcast

EVQLV’s CEO, Andrew Satz, joined Kerrin Black of the Talent Finders Podcast to discuss his entrepreneurial journey, some of the challenges facing AI for drug discovery, his legacy and much more.

Pin It on Pinterest